natgillin/translations-raw huggingface dataset:
Det primære mål for virkningen var baseret på, hvor meget patientens primære hjernetumor var skrumpet efter seks måneders behandling.
The main measure of effectiveness was based on how much the patient’s main brain tumour shrank after six months of treatment.
Det primære mål for virkningen var indholdet af hepatitis C- virus i blodet før og efter seks måneders eller et års behandling og ved opfølgningen seks måneder senere.
The main measure of effectiveness was the level of hepatitis C virus circulating in the blood before and after six months or a year of treatment, and at ‘follow-up’, six months later.
Det primære mål for virkningen var mængden af antistoffer mod influenzavirusset i patienternes blod før vaccination, på datoen for anden injektion (dag 22) og 21 dage senere (dag 43).
The main measures of effectiveness were the levels of antibodies against the flu virus in the patients’ blood before vaccination, on the day of the second injection (day 22), and 21 days later (day 43).
Det primære mål for virkningen var risikoen for klinisk forværring (at patienternes sygdom blev forværret).
The main measure of effectiveness was the risk of clinical failure (the patients’ disease getting worse).
Det primære mål for virkningen var tilstedeværelsen af antistoffer mod viraene i den vaccinerede kats blod.
The main measure of effectiveness was the presence of antibodies against the viruses in the vaccinated kittens’ blood.
Det primære mål for virkningen var ændringen i patientens nyrefunktion efter 18 måneders behandling.
The main measure of effectiveness was the change in patients’ kidney function after 18 months of treatment.
Det primære mål for virkningen var ændringen i patienternes manisymptomer efter seks uger målt på en standardskala.
The main measure of effectiveness was the change in the patients’ symptoms of mania after six weeks on a standard scale.
Det primære mål for virkningen var ændringerne i den distance, patienterne kunne gå på seks minutter efter 12 ugers behandling.
The main measure of effectiveness was the change in the distance the patients could walk in six minutes after 12 weeks of treatment.
Det primære mål med dette studie var at fastslå, om dabigatranetexilat var non- inferior til warfarin i at reducere forekomsten af det sammensatte endepunkt af apopleksi og SE.
The primary objective in this study was to determine if dabigatran etexilate was non-inferior to warfarin in reducing the occurrence of the composite endpoint stroke and SEE.
Det primære parameter til måling af virkning var baseret på lægens og patientens vurdering af, hvor godt behandlingen virkede med hensyn til at forebygge og behandle blødningsepisoder.
The main measure of effectiveness was based on the doctor’s and patient’s assessment of how well the treatment worked in preventing and treating bleeding episodes.
Det primære PFS-effektmål, ORR og DCR var baseret på en centraliseret, uafhængig blindet gennemgang af billede-data.
The PFS primary endpoint, ORR and DCR were based on centralized, independent blinded review of the imaging data.
Det primære plasmaprotein, som binder aclidiniumbromid, er albumin.
The main plasma protein that binds aclidinium is albumin.
Det primære resultatmål var “Neuropathy Impairment Score of the Lower Limb” (NIS-LL – en lægelig vurdering af den neurologiske undersøgelse af underekstremiteterne) og livskvalitetsundersøgelsen, Norfolk Quality of Life – Diabetic Neuropathy (Norfolk QOL-DN – en patientvurdering, total livskvalitetsscore [TQOL]).
The primary outcome measures were the Neuropathy Impairment Score of the Lower Limb (NIS-LL – a physician assessment of the neurologic exam of the lower limbs) and the Norfolk Quality of Life - Diabetic Neuropathy (Norfolk QOL-DN – a patient reported outcome, total quality of life score [TQOL]).
Det primære sikkerhedsmål (større blødning) forekom hos 6 (0,6 %) og 4 (0,8 %) patienter i hhv. rivaroxaban-gruppen (n = 988) og VKA-gruppen (n = 499) (RR 0,76; 95 % KI 0,21-2,67; sikkerhedspopulation).
The principal safety outcome (major bleeding) occurred in 6 (0.6 %) and 4 (0.8 %) patients in the rivaroxaban (n = 988) and VKA (n = 499) groups, respectively (RR 0.76; 95 % CI 0.21- 2.67; safety population).
Det primære sikkerhedsmål (større blødning) forekom hos 6 (0,6 %) og 4 (0,8 %) patienter i hhv. rivaroxabangruppen (n = 988) og VKA-gruppen (n = 499) (RR 0,76; 95 % KI 0,21-2,67; sikkerhedspopulation).
The principal safety outcome (major bleeding) occurred in 6 (0.6 %) and 4 (0.8 %) patients in the rivaroxaban (n = 988) and VKA (n = 499) groups, respectively (RR 0.76; 95 % CI 0.21- 2.67; safety population).
Det primære slutmål for effekt var i alle fire studier antallet af patienter i hver gruppe, som opnåede PASI 75 (dvs. mindst 75 % forbedring i Psorisis- arealet og på Severity Index- scoren i forhold til baseline) efter 12 ugers behandling.
The primary efficacy endpoint in all four studies was the proportion of patients in each treatment group who achieved the PASI 75 (i.e., at least a 75% improvement in the Psoriasis Area and Severity Index score from baseline) at 12 weeks.
Det primære slutmål for effekt var i alle tre studier antallet af patienter i hver gruppe, som opnåede PASI 75 (dvs mindst 75 % forbedring i Psorisis Arealet og på Severity Index scoren i forhold til baseline) efter 12 ugers behandling.
The primary efficacy endpoint in all four studies was the proportion of patients in each treatment group who achieved the PASI 75 (i.e., at least a 75% improvement in the Psoriasis Area and Severity Index score from baseline) at 12 weeks.
Det primære slutmål i alle undersøgelser var andelen af patienter med en  75 % forbedring af ”Psoriasis Area and Severity Indexscore” (PASI 75-respons) i forhold til udgangsværdien bedømt en uge efter en 12-ugers behandlingsperiode.
In all studies, the primary endpoint was the proportion of patients with a  75% improvement in the Psoriasis Area and Severity Index score (a PASI 75 response) relative to baseline when assessed one week after a 12-week treatment course.
Det primære slutpunkt i studie var skeletal morbidity period rate (SMPR).
The primary endpoint of the trial was the skeletal morbidity period rate (SMPR).
Det primære udfald – de kombinerede slutpunkter for dødsfald eller BPD (bronchopulmonal dysplasi) ved 36 gestationsuger – adskilte sig ikke signifikant i grupperne, heller ikke med en justering for gestationsalder som kovariat (p=0,40) eller med fødselsvægt som kovariat (p=0,41).
The primary outcome, of the combined efficacy endpoints of death or BPD at 36 weeks GA, was not significantly different between groups, even with adjustment for gestational age as a covariate (p = 0.40), or with birth weight as a covariate (p = 0.41).
Det primære virkningsendepunkt i studie MCL-002 var progressionsfri overlevelse (PFS).
The primary efficacy endpoint in Study MCL-002 was progression-free survival (PFS).
Det primære virkningsendepunkt var forekomst af verificeret/sandsynlig IFI bestemt af et uafhængigt, blindet eksternt ekspertpanel i on-treatment
The primary efficacy endpoint was the incidence of proven/probable IFIs as determined by an independent, blinded external expert panel during the on-treatment period.
Det primære virkningsendepunkt, baseret på investigatorbedømt tumorrespons, var progressionsfri overlevelse (PFS), for lenvatinib plus everolimus-armen vs everolimus-armen og for lenvatinib-armen vs everolimus-armen.
The primary efficacy outcome measure, based on investigator assessed tumour response, was progression-free survival (PFS) of the lenvatinib plus everolimus arm vs the everolimus arm and of the lenvatinib arm vs the everolimus arm.
Det primære virkningsendepunkt, fuldstændig respons (CR: ingen opkastning, ingen opkastningsfornemmelser og ingen antiemetisk nødmedicin) i løbet af de første 24 timer efter operationen, blev nået hos 78,2 % af patienterne i palonosetron-gruppen, og hos 82,7 % i ondansetron-gruppen.
The primary efficacy endpoint, Complete Response (CR: no 1o0miting, no retching, and no antiemetic rescue medication) during the first 24 hours postoperatively was achieved in 78.2% of patients in the palonosetron group and 82.7% in the ondansetron group.
Det primære virkningsmål var samlet overlevelse.
The primary endpoint was overall survival.
Det primære virkningsudfald var progressionsfri overlevelse (PFS) bestemt via blindet, uafhængig radiologisk gennemgang ved brug af Response Evaluation Criteria in Solid Tumours (RECIST) 1.1. Sekundære målinger af virkningsudfaldet omfattede samlet responsrate og samlet overlevelse.
The main efficacy outcome measure was progression-free survival (PFS) as determined by blinded independent radiologic review using Response Evaluation Criteria in Solid Tumours (RECIST) 1.1. Secondary efficacy outcome measures included overall response rate and overall survival.
Det produceres af celler, der har fået indsat et gen (DNA), som gør dem i stand til at producere det humane interferon.
This means that it is made by cells that have received a gene (DNA), which makes them able to produce the human interferon.
Det produceres i store mængder hos patienter med leddegigt og forårsager ledbetændelse og ledbeskadigelser, og er med til at fremkalde betændelse ved CAPS.
This messenger is produced in high levels in patients with rheumatoid arthritis, causing inflammation of the joints and joint damage, and is also involved in the inflammation associated with CAPS.
Det produceres via en metode, der er kendt som ‘rekombinant DNA-teknologi’: Hormonet produceres af en bakterie, der har modtaget et gen (DNA), som gør den i stand til at producere dette stof.
It is produced by a method known as ‘recombinant DNA technology’: the hormone is made by a bacterium that has received a gene (DNA) that makes it able to produce it.
Det produceres via en metode, der er kendt som ‘rekombinant DNA-teknologi’: Hormonet produceres af en bakterie, der har modtaget et gen (DNA), som gør den i stand til at producere somatropin.
It is produced by a method known as ‘recombinant DNA technology’: the hormone is made by bacteria into which a gene (DNA) has been introduced that makes them able to produce somatropin.
Det prospektive, randomiserede studie (UKPDS) har påvist en positiv langtidsvirkning af tæt blodglukosekontrol ved type 2-diabetes.
The prospective randomised (UKPDS) study has established the long-term benefit of intensive blood glucose control in type 2 diabetes.
Det prospektive, randomiserede studie UKPDS (UK Prospective Diabetes Study) har fastslået den langsigtede fordel ved intensiv styring af blodsukker ved type 2-diabetes.
The prospective randomised UKPDS (UK Prospective Diabetes Study) study has established the long- term benefit of intensive blood glucose control in type 2 diabetes.
Det påkrævede samlede volumen rekonstitueret Inflectra- opløsning beregnes.
The required total volume of reconstituted Inflectra solution has to be calculated.
Det påkrævede samlede volumen rekonstitueret Remsima- opløsning beregnes.
The required total volume of reconstituted Remsima solution has to be calculated.
Det påkrævede totale volumen bestemmes udfra vægten af patienten i overensstemmelse med anbefalingerne i nedenstående tabel.
The total volume required is determined by the weight of the patient according to the recommendation in the table below.
Det påkrævede volumen af den rekonstituerede Inflectra-opløsning fortyndes til 250 ml med natriumchlorid 9 mg/ml (0,9 %) infusionsvæske.
The required volume of the reconstituted Inflectra solution should be diluted to 250 mL with sodium chloride 9 mg/mL (0.9%) solution for infusion.
Det påkrævede volumen af rekonstitueret Inflectra-opløsning tilføjes langsomt til 250 ml infusionsflasken eller –posen og blandes forsigtigt.
The required volume of reconstituted Inflectra solution should slowly be added to the 250-mL infusion bottle or bag and gently be mixed.
Det påkrævede volumen af rekonstitueret Remsima-opløsning tilføjes langsomt til 250 ml infusionsflasken eller –posen og blandes forsigtigt.
The required volume of reconstituted Remsima solution should slowly be added to the 250-mL infusion bottle or bag and gently be mixed.
Det radioaktivt mærkede lægemiddel gives derefter til patienten efter anvisningerne i produktresuméet for det pågældende lægemiddel.
The radiolabelled medicine is then given to the patient according to the instructions in that medicine’s product information.
Det radioaktivt mærkede lægemiddel gives derefter til patienten i overensstemmelse med produktresuméet for det pågældende lægemiddel.
The radiolabelled medicine is then given to the patient according to the instructions in that medicine’s summary of product characteristics (SmPC).
Det radioaktivt mærkede præpa- rat skal anvendes senest 6 timer efter, at det er fremstillet.
The radiolabelled product is to be used within 6 hours of its preparation.
Det radiomærkede lægemiddel anvendes til behandling af voksne patienter med follikulær B-celle non-Hodgkins lymfom.
The radiolabelled medicine is used to treat adult patients with follicular B cell non Hodgkin’s lymphoma.
Det radiomærkede lægemiddel gives herefter til patienten i overensstemmelse med anvisningerne i indlægssedlen.
The radiolabelled medicine is then given to the patient according to the instructions in that medicine’s summary of product characteristics (SmPC).
Det rapporteredes, at 6 % fik en lokal reaktion på subkutan administration, for det meste rødmen.
Six percent of patients had an adverse local reaction to subcutaneous administration, mostly redness.
Det re- produktive system og mammae
Reproductive system and breast disorders
Det reducerer betændelsen ved at mindske dannelsen af immunceller kaldet "lymfocytter", som forårsager betændelsen.
It reduces inflammation by reducing the production of immune cells called ‘lymphocytes’, which are responsible for inflammation.
Det reducerer de negative virkninger på hjerte og tarm og nedsætter risikoen for bivirkninger.
This reduces its negative effects on the heart and the gut, making it less likely to cause side effects.
Det reducerer desuden udskillelsen af felin viral rhinotracheitis vira, forebygger et fald i antallet af hvide blodlegemer ved felin panleukopeni, og forhindrer, at der forbliver FeLV i blodet.
In addition, it reduced the excretion of feline viral rhinotracheitis viruses, prevented a fall in white blood cell counts in feline panleucopenia and prevented FeLV from remaining in the blood.
Det reducerer inflammationen ved at begrænse dannelsen af immunceller kaldet »lymfocytter«, som forårsager inflammationen.
It reduces inflammation by reducing the production of immune cells called ‘lymphocytes’, which are responsible for inflammation.
Det reducerer inflammationen ved at begrænse dannelsen af immunceller kaldet ‘lymfocytter’, som forårsager inflammationen.
It reduces inflammation by reducing the production of immune cells called ‘lymphocytes’, which are responsible for inflammation.
Det reducerer inflammationen ved at begrænse dannelsen af immunceller kaldet ”lymfocytter”, som forårsager inflammationen.
It reduces inflammation by reducing the production of immune cells called ‘lymphocytes’, which are responsible for inflammation.
Det reducerer leukocytinfilyration i inflammeret væv.
It reduces leukocyte infiltration into the inflamed tissue.
Det reducerer risikoen for, at du får en ny blodprop i hjertet, et slagtilfælde, eller for at du dør som følge af hjertekarsygdom.
It reduces the chances of you having another heart attack, stroke or dying from a disease related to your heart or blood vessels.
Det regnes ikke for muligt at fjerne valsartan ved hæmodialyse.
Valsartan is unlikely to be removed by haemodialysis.
Det rekombinante humane hyaluronidase skal være klart og farveløst.
The recombinant human hyaluronidase should be clear and colourless.
Det rekonstituerede hætteglas med 10 ml 0,9% natriumchloridinjektionsvæske (normalt saltvand) indeholder 11,5 mmol (265 mg) natrium.
The reconstituted vial with 10 mL of 0.9% sodium chloride (normal saline) for injection contains 11.5 mmol (265 mg) of sodium.
Det rekonstituerede hætteglas skal anvendes med det samme.
The reconstituted vial should be used immediately.
Det rekonstituerede koncentrat er en klar, farveløs eller let gullig opløsning, i alt væsentligt fri for synlige partikler.
The reconstituted solution results in a clear, colourless or slightly yellowish solution, essentially free of visible particles.
Det rekonstituerede koncentrat er farveløst til let gulligt og klart til meget opaliserende.
The reconstituted solution is colourless to slightly yellow, and clear to very opalescent.
Det rekonstituerede koncentrat fortyndes med natriumchloridopløsning 9 mg/ml (0,9 %) til infusion eller med glucose 50 mg/ml (5 %) infusionsopløsning.
The reconstituted solution should be diluted with sodium chloride 9 mg/ml (0.9%) solution for infusion or glucose 50 mg/ml (5%) solution for infusion.
Det rekonstituerede koncentrat indeholder 0,05 mg/ml trabectedin.
This reconstituted solution contains 0.05 mg/ml of trabectedin.
Det rekonstituerede koncentrat kan opbevares i op til 24 timer ved 25 C eller derunder.
This reconstituted solution may be stored for up to 24 hours at or below 25°C.
Det rekonstituerede koncentrat kan opbevares i op til 24 timer ved 25C eller derunder.
This reconstituted solution may be stored for up to 24 hours at or below 25°C.
Det rekonstituerede koncentrat og den fortyndede infusionsvæskes kemiske og fysiske stabilitet efter anbrud er påvist i 24 timer ved 25°C. Ud fra et mikrobiologisk synspunkt bør præparatet anvendes snarest muligt, og inden for 3 timer efter rekonstituering og fortynding.
Chemical and physical in use stability of the reconstituted solution has been demonstrated for 24 hours at 25 °C. From a microbiological point of view, the product should be used as soon as possible but within 3 hours of reconstitution and dilution.
Det rekonstituerede koncentrat skal fortyndes yderligere før administration.
Reconstituted concentrate must be further diluted prior to administration.
Det rekonstituerede koncentrat skal fortyndes yderligere med 50 mg/ml (5 %) glucoseinfusionsvæske.
The reconstituted concentrate must be further diluted with 50 mg/ml (5 %) glucose solution for infusion.
Det rekonstituerede koncentrat skal straks overføres fra hætteglasset til infusionsposen.
The reconstituted solution should be transferred from the vial into the infusion bag immediately.
Det rekonstituerede koncentratskal undersøges visuelt for partikler eller misfarvning.
Reconstituted solutions should be visually inspected for particulate matter or discolouration.
Det rekonstituerede lægemiddel er en klar og farveløs opløsning
The reconstituted medicinal product is a clear and colourless solution.
Det rekonstituerede lægemiddel fortyndes til 250 ml med 9 mg/ml (0,9 %) natriumchloridinjektionsvæske, 4,5 mg/ml (0,45 %) natriumchloridinjektionsvæske eller Ringer-lactat injektionsvæske.
The reconstituted medicinal product is diluted to 250 ml with sodium chloride 9 mg/ml (0.9%), sodium chloride 4.5 mg/ml (0.45%), or Lactated Ringer’s solution for injection.
Det rekonstituerede lægemiddel skal anvendes med det samme.
The reconstituted product should preferably be used immediately.
Det rekonstituerede lægemiddel skal anvendes straks.
The reconstituted medicinal product should be used immediately.
Det rekonstituerede lægemiddel skal anvendes straks.
The reconstituted product should be used immediately.
Det rekonstituerede lægemiddel skal anvendes umiddelbart.
The reconstituted medicinal product should be used immediately.
Det rekonstituerede lægemiddel vil fremstræde klart til svagt opaliserende, farveløs til lys brunlig-gul.
The reconstituted medicinal product will appear clear to slightly opalescent, colourless to pale brownish-yellow.
Det rekonstituerede NovoEight skal injiceres i en vene (intravenøs injektion).
The reconstituted NovoEight must be injected into your vein (intravenous injection).
Det rekonstituerede produkt bør injiceres intravenøst én gang daglig, 3 dage i træk.
The reconstituted product should be injected intravenously once daily for 3 consecutive days.
Det rekonstituerede produkt bør injiceres subkutant en gang daglig, 5 dage i træk.
The reconstituted product should be injected subcutaneously once daily for 5 consecutive days.
Det rekonstituerede produkt er en klar, farveløs opløsning uden partikler.
The reconstituted product is a clear, colourless solution without particles.
Det rekonstituerede produkt er uden konserveringsmidler og skal anvendes umiddelbart efter præparation.
The reconstituted product is preservative free and should be used immediately after preparation.
Det rekonstituerede produkt indeholder ingen konserveringsmidler og skal anvendes umiddelbart efter klargøring.
The reconstituted product is preservative free and should be used immediately after preparation.
Det relative antal af ADPKD-relaterede hændelser faldt med 13,5 % hos tolvaptan-behandlede patienter, (hazard ratio, 0,87; 95 % CI, 0,78 til 0,97; p=0,0095).
The relative rate of ADPKD-related events was decreased by 13.5% in tolvaptan-treated patients, (hazard ratio, 0.87; 95% CI, 0.78 to 0.97; p=0.0095).
Det relevante volumen koncentrat trækkes fra hætteglasset og tilsættes en infusionspose indeholdende 250 ml natriumchlorid 4,5 mg/ml (0,45%) infusionsvæske eller natriumchlorid 9 mg/ml (0,9%) infusionsvæske.
The appropriate amount of solution should be withdrawn from the vial and added to an infusion bag containing 250 mL of sodium chloride 4.5 mg/ml (0.45%) solution for infusion or sodium chloride 9 mg/ml (0.9%) solution for infusion.
DEt reproductive system og mammae
Reproductive system and breast disorders
Det reproductive system og mammae:
Reproductive system and breast disorders
Det reproduktive
Cardiac disorders
Det reproduktive
disorders
Det reproduktive
Reproductive
Det reproduktive
Reproductive system and breast disorders
Det reproduktive system og
Reproductive system and breast
Det reproduktive system og Ikke almindelig: Seksuel dysfunktion, ændret libido  mammae:
Reproductive system and breast Uncommon: sexual dysfunction, libido changes  disorders:
Det reproduktive system og mammae
breast disorders
Det reproduktive system og mammae
Ear and labyrinth disorders
Det reproduktive system og mammae
Gastrointestinal
Det reproduktive system og mammae
Gastrointestinal disorders
Det reproduktive system og mammae
General disorders
Det reproduktive system og mammae
General disorders and administration site conditions
Det reproduktive system og mammae
Immune system disorders
Det reproduktive system og mammae
MedDRA system organ class
Det reproduktive system og mammae
Metrorrhagia
Det reproduktive system og mammae
Musculoskeletal and connective tissue disorders
Det reproduktive system og mammae
Nervous system disorders
Det reproduktive system og mammae
Rare ( 1/10000 and
Det reproduktive system og mammae
Renal and urinary disorders
Det reproduktive system og mammae
Reproductive and breast disorders
Det reproduktive system og mammae
Reproductive system and
Det reproduktive system og mammae
Reproductive system and breast
Det reproduktive system og mammae
Reproductive system and breast disorders Common:
Det reproduktive system og mammae
Reproductive system, and breast disorders
Det reproduktive system og mammae
Reproductive systems and
Det reproduktive system og mammae
Skin and subcutaneous tissue disorders
Det reproduktive system og mammae
System Organ Class
Det reproduktive system og mammae
System Organ Class Frequency
Det reproduktive system og mammae
Vascular disorders
Det reproduktive system og mammae
ystem and breast disorders
Det reproduktive system og mammae Almindelig: Mildt eller moderat OHSS Ikke almindelig: Alvorligt OHSS, brystsmerter
Reproductive system and breast disorders Common: Mild or moderate OHSS Uncommon: Severe OHSS, breast pain
Det reproduktive system og mammae: Almindelig
Reproductive system and breast disorders
Det reproduktive system og mammae: ikke almindelig: gynækomasti
Reproductive system and breast disorders: uncommon: gynaecomastia
Det reproduktive system og mammæ
Photosensitivity
Det reproduktive system: Impotens (manglende evne til at opretholde en erektion)
Reproductive system disorders: Impotence (inability to maintain an erection)
Det respiratoriske system
Respiratory system